Method validation for the one-month stability study of trans-resveratrol in human plasma

Jundishapur Journal of Natural Pharmaceutical Products

Volumn 8, Issue 2, 2013, Pages 65-69

  Iranshahy, Milad ^a,b   Mohammadpoor, Amir Hooshang ^b   Hassanzadeh Khayy at, Mohammad ^b   Iranshahi, Mehrdad ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidants; Resveratrol; Stability

Indexed keywords

ASCORBIC ACID; RESVERATROL; TOLUENE;

ARTICLE; BLOOD PH; DRUG BLOOD LEVEL; DRUG STABILITY; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ILLUMINATION; ISOMERIZATION; MEASUREMENT ACCURACY; NORMAL HUMAN; QUANTITATIVE ANALYSIS; TEMPERATURE; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS;

EID: 84881533764     PISSN: 17357780     EISSN: 22287876     Source Type: Journal    
DOI: 10.5812/jjnpp.9566     Document Type: Article

References (18)

1. Fremont L, Belguendouz L, Delpal S. Antioxidant activity of res-veratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 1999;64(26):2511-21.
2. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med. 2002;33(3):387-98.
3. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. ToxicolApplPharmacol. 2007;224(3):274-83.
4. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomedi-cine&pharmacotherapy. 2002;56(2):84-7.
5. Das M, Das DK. Resveratrol and cardiovascular health. Mol Aspects Med. 2010;31(6):503-12.
6. Shetty AK. Promise of resveratrol for easing status epilepticus and epilepsy. Pharmacol Ther. 2011;131(3):269-86.
7. Evans WC. Trease and Evans pharmacognosy. Saunders/Elsevier Edinburgh, Scotland; 2009.
8. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev. 2004;22(3):169-88.
9. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol NutrFood Res. 2005;49(5):472-81.
10. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50(11):3337-40.
11. Fremont L. Biological effects of resveratrol. Life Sci. 2000;66(8):663.
12. Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. Ann NY Acad Sci. 2011;1215:16-21.
13. Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl). 2002;115(3):378-80.
14. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011.
15. Trela BC, Waterhouse AL. Resveratrol: isomeric molar absorptivi-ties and stability. J Agric Food Chem. 1996;44(5):1253-7.
16. Juan ME, Maijo M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal. 2010;51(2):391-8.
17. N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Car-pentier R, Hotchandani S, et al. Resveratrol binding to human serum albumin. JBiomol Struct Dyn. 2006;24(3):277-83.
18. Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X, et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm. 2011;416(2):433-42.